Kyverna Therapeutics Shares Jump on Positive One-Year Cell Therapy Data

Shares of Kyverna Therapeutics (KYTX) surged 8.1% in pre-open trading after the company announced positive one-year topline data from two clinical trials for its CAR T-cell therapy candidate, mivocabtagene autoleucel (miv-cel).

Key Clinical Findings

Kyverna reported encouraging results from its KYSA-8 registrational trial evaluating miv-cel in 26 adult patients with stiff person syndrome (SPS). The company highlighted the durability of the treatment's effect, a key consideration for investors in cell therapy.

Key one-year data points from the SPS trial include:

• A median 49% improvement in the timed 25-foot walk, an increase from the 46% improvement observed at week 16.
• 67% of patients who previously required walking aids remained assistance-free.
• 92% of patients stayed free of chronic immunotherapies.
• No high-grade adverse events were reported, signaling a favorable safety profile.

Kyverna also noted encouraging longer-term follow-up results from the Phase 2 portion of its KYSA-6 trial in patients with generalized myasthenia gravis, another autoimmune disorder.

Regulatory and Market Impact

Ad

The positive data has direct regulatory implications. Kyverna confirmed it intends to incorporate the one-year SPS results into its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA). The company stated that the BLA submission remains on track for completion in the fourth quarter of 2026.

The stock's strong performance was a company-specific event, standing in sharp contrast to the broader market, which saw the S&P 500 and Nasdaq open lower. The company filed a Form 8-K with the SEC detailing the results and held an investor call to discuss the findings.

Context and Outlook

The update reinforces a bullish analyst consensus on Kyverna, which held a "Strong Buy" rating ahead of the announcement. Investors are reacting to the combination of miv-cel's durable clinical effect, its clean safety profile across two separate indications, and a clear timeline for its BLA submission.

Kyverna plans to present additional data from both trials at upcoming medical conferences, including the AANEM Annual Meeting on September 29 and the joint ACTRIMS-ECTRIMS meeting in October.